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ABSTRACT
The pathogenicity and intractable nature of the microorganism Staphylococcus aureus (SA) has
been long documented and highlighted by many health care agencies, with emphasis on its
ability to exploit the human coagulation system to deadly effect. Two drugs from a class of
inhibitors known as Direct Thrombin Inhibitors (DTI) have been shown to have a substantial
effect on the enzyme secreted by SA known as Staphylocoagulase (SC), but up until now the
application of this potential treatment has been limited. This paper strives to supply an overview
of these clinical studies and propose a novel protocol for testing DTI’s on SA in an in vitro
setting. Three DTIs have been identified, including two already tested in clinical trials, and
computational molecular docking simulations have been applied to elucidate the mechanisms of
action for the inhibition. An additional DTI has been developed using these mechanisms as
principles and shows promise for future development. After conducting this preliminary
protocol, it has been found that running a minimum inhibitory concentration test across several
tubes with varying degrees of these DTIs demonstrated varying levels of coagulation consistent
with the findings of clinical research papers. It is fair to conclude, then, that after development or
discovery of new coagulase inhibitors, they can be quickly and accurately tested against existent
DTIs to gauge their efficacy.
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CHAPTER 1: INTRODUCTION
1.1 Statement of the Problem
Staphylococcus aureus (SA) is an opportunistic pathogen responsible for many
nosocomial and post-operative infections. SA is a common human commensal that colonizes the
upper nasopharynx in many normal, healthy humans. When transfected to the site of a wound or
open sore, however, SA can cause painful and life-threatening infections, especially in the
elderly and immunocompromised population. In a hospital setting, however, certain strains of
SA have become resistant to the antibiotics used to treat them and can pose a threat to anyone in
a hospital, immunocompromised or otherwise. These strains are commonly referred to as MRSA
or VRSA (methicillin-resistant or vancomycin-resistant Staphylococcus aureus). It is for this
reason that SA is on the High Priority list from the World Health Organization for the
development of new antibiotics (Tacconelli, 2017).
SA possesses many virulence factors that either help it penetrate bodily tissue or evade
the host’s immune system. It has been demonstrated that one of the ways SA protects itself from
the patient’s immune system is through a protein called coagulase, which hijacks the natural
coagulation process in the body, causing controlled clots to form around the bacterial colonies
(McAdow, 2012). This allows SA to migrate around the body without risk of destruction from
the body’s immune system and attach to hard surfaces. When it attaches to a heart valve, this is
called infective endocarditis, and SA is the leading causes of bacterial endocarditis worldwide
(Fowler, 2005).
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As a result of this high virulence, SA’s coagulase property has been the target of much
investigation to elucidate the underlying mechanism. As it turns out, the clotting is caused by an
enzyme called Staphylocoagulase (SC) binding to the human pro-enzyme prothrombin, causing
it to behave like its activated form, thrombin (Liesenborghs, 2018). This is done by coagulase
through inserting a portion of itself into prothrombin, illustrated in Figure 1 by a “tooth” piercing
the enzyme, and activating it, without cleavage.
Figure 1: Diagram showing a cartoon representation of activation of prothrombin by
prothrombinase (top), activation of prothrombin by coagulase (bottom)

This new enzyme complex is known as Staphylothrombin (ST). In the normal
coagulation cascade, thrombin is activated to convert the monomer fibrinogen to the active
polymer fibrin, which is the primary constituent of a healthy clot. In this inappropriate coagulase
cascade, however, SC diffuses from the SA colonies, attaches itself to the host prothrombin
enzyme, and begins depositing large quantities of fibrin locally around the colony. SA also
contains “sticky” proteins that allow fibrin to bind more readily to its surface, coating the
bacterial colonies in a tough, thick biofilm made from host proteins, indistinguishable to the
host’s immune system.
2

Figure 2: Staphylococcus aureus can form biofilms that break off to form metastatic
colonies

If any part of the colony breaks off from the rest, it can very easily find its way into another part
of the host’s circulatory system, and lodge into the vascular endothelium. If this occurs, it
presents as bacterial metastasis. Bacterial metastasis refers to the inability of the immune system
to keep up with the bacterial population, resulting in circulating bacteria that can establish
colonies in dangerous places in the body. This can be indicated and even exasperates septic
shock, an often-fatal complication of bacterial metastasis. This turns a local, uncomplicated
infection of a wound site into a systemic, complex infection with multiple sites. If the SA
subtype happens to be one of the antibiotic resistant organisms mentioned previously, the
infection is all but untreatable and has a 20-50% mortality rate (Kaye, 2008).
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1.2 Proposed Solution
While the outlook for treatment of these antibiotic-resistant strains may be bleak, an
interesting consequence of the structural relationship between ST and activated thrombin is that
it has been theorized that an inhibitor of thrombin can also inhibit coagulase. Such a class of
drugs would have no interaction with the normal forms of antibiotic resistance that MRSA and
VRSA possess, instead targeting a specific virulence factor. There exists a class of drugs known
as Direct Thrombin Inhibitors (DTI) that were developed to prevent thrombosis in patients who
for various reasons could not have heparin or warfarin administered to them (Nisio, 2005). As
their name suggests, DTIs are direct, competitive inhibitors of the active enzyme thrombin, and
act by binding to the active site of the enzyme, preventing its function. While the other drugs
mentioned target parts of the pathways upstream of thrombin, which can have detrimental effects
to other parts of the coagulation and inflammatory response, DTIs exclusively target the enzyme
responsible for the conversion of soluble fibrinogen to insoluble, polymeric fibrin. Drugs in this
class can be subdivided into the univalent DTIs, which contain Dabigatran, Argatroban, and
Melagatran, and the bivalent DTIs, which include Hirudin, Bivalirudin, and others. For the
purposes of simplicity, this paper will refer to univalent DTIs as simply DTIs, while referring to
bivalent DTIs specifically.
As previously stated, ST has a striking structural and functional similarity to thrombin,
lending itself to inhibition by this class of drugs. If inhibited, SA would no longer be able to
protect itself with coagulation and would be exposed to the host’s immune response. A potential
downside of this therapy however, is that DTIs inhibit both ST and normal, activated thrombin in
response to the coagulation cascade, as a result, a patient given a DTI for a SA infection may be
at an increased bleeding risk, which could compound mortality in an already dire situation.
4

1.3 Literature Review
In order to further understand the breadth of research conducted in this area, a literature
review has been conducted. First, in a previously cited paper, “Staphylococcus aureus, master
manipulator of the human hemostatic system” (Liesenborghs, 2018), points out the mechanism of
action that is unique to coagulase. In normal thrombotic activation, an enzyme known as
prothrombinase enzymatically cleaves prothrombin from a 72 kiloDalton (kDA) proenzyme, to a
36 kDa enzyme. This results in a freshly cleaved, “loose” N-terminal region, which then reinserts
into thrombin, thereby becoming activated. Coagulase, on the other hand, does not cleave
prothrombin into the active form, instead inserting its own N-Terminal region that closely
resembles the thrombin N-Terminus, thereby activating it. This creates a large (136 kDa)
coagulase-prothrombin complex, with a similar active site.
This complex is not completely identical to thrombin, however, and this is demonstrated
in the effect that no inhibitory ligand other than univalent direct thrombin inhibitors that bind to
thrombin can bind to the coagulase-prothrombin complex. In addition, many bivalent DTIs have
limited FDA approval, and in preliminary testing demonstrated inefficacy with ST, due to the
binding of SC blocking a regulatory site called Exosite 1 on the surface of prothrombin. Note in
Figure 3 the process from Coagulase into prothrombin, connecting the two, the “tooth”
previously noted. This is where in normal states prothrombin would be cleaved and restructured,
but in this case no cleavage is necessary for Staphylothrombin to become enzymatically
activated.
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Figure 3: Molecular visualization of the insertion of N-Terminus region (red) into
Prothrombin (blue) by Coagulase (salmon). PDB ID: 1NU9 (Friedrich, 2003)

Now that the underlying mechanism in the literature has been reviewed, the clinical
literature shows even greater promise. Two groundbreaking studies of this potential treatment
have been performed, both with promising results.
One, titled “Targeting Coagulase Activity in Staphylococcus aureus Bacteraemia: A
Randomized Controlled Single-Centre Trial of Staphylothrombin Inhibition” (Peetermans, 2018)
identified 94 patients who experienced SA bacteremia. They were split into 2 equal groups of 47,
one group received the standard treatment of antibiotics, and in addition received a Low
Molecular Weight Heparin, which has no interaction with ST. This group acted as a control
group. The testing group of another 47 received a DTI, either Dabigatran orally or Argatroban
intravenously, until the level in their blood stream was about equal and clinically relevant.
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The results showed that patients who were treated with DTIs showed lower levels of Ddimer (an indicator for inflammation and coagulation) as well as lower positive blood cultures,
when compared to a control. In addition, there were no differences in any other inflammatory
factors, clinically relevant bleeding, and thrombotic complications. The paper concluded that:
“Targeting Staphylothrombin with DTIs is feasible in a subset of S. aureus bacteraemic patients,
with comparable safety to standard thromboprophylaxis. In future studies of Staphylothrombin
inhibition, feasibility can be further improved by rapid diagnostics.”
Figure 4: Diagram showing a cartoon representation of inhibition of thrombin by a
univalent DTI (top), and inhibition of Staphylothrombin by a DTI (bottom)

Another study explored the potential protective nature that DTIs exhibit with respect to
medical implants, such as venous catheters. The paper titled “The Role of StaphylothrombinMediated Fibrin Deposition in Catheter-Related Staphylococcus aureus Infections” notes that
fibrin deposition facilitates the adhesion of S. aureus to catheters, resulting in a disease
complication called catheter-related bloodstream infections (CRBSIs), which can have a fatality
rate of up to 35%. When catheters were submerged in a solution containing plasma, SA, and
either Dabigatran or Argatroban, there was no measurable increase in fibrin deposition when
7

compared to samples lacking the DTIs, or samples that contained non-DTI anticoagulants, such
as low molecular weight heparin (LMWH).
The researchers went on to test catheters that had a thin layer of fibrin already deposited,
which still showed decreased fibrin deposition when compared to the controls. This further
demonstrates that catheter infections could be prevented and significantly slowed with the
administration of DTIs.
The study also used in vivo mouse models to elucidate the effect of these catheter related
infections on other organ systems, in order to determine the ability of DTIs to prevent the
infectious metastasis of SA. They found that the absence or inhibition of ST resulted in
significantly reduced distant infectious complications, which they tested by measuring bacterial
load on the kidneys in mouse models. (Vanassche, 2013)
The literature on SA coagulase is extensive, but to understand the nature of binding and
inhibition, it is necessary to look in depth at the structure of ST through molecular studies, and to
do that it is useful to form a broad library of substances that can bind and inhibit ST. This will
provide an overview of the substances that bind to ST, how they bind, and what can be done to
help develop more molecules like them in the future.
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CHAPTER 2: METHODS AND MATERIALS
2.1 Molecular Docking Studies
In order to further explore the mechanism of the binding of DTIs to ST, thus causing
inhibition, a molecular docking review was conducted using several DTIs as potential ligands.
Figure 5 details the encompassing theory behind this process. The resources available from the
National Center for Biotechnology Information, specifically the PubChem database and the builtin derivative function, were used to develop a large ligand library (Kim, 2019). Several of these
promising potential ligands were identified in a screening process. The program Autodock, in the
parent program PyRx was used to perform molecular docking protocols (Dallakyan, 2015),
which produced comparable ΔG values, also known as binding Affinity, in kcal/mole. It was
found that the three DTIs tested exhibited nearly identical binding patterns when bound to
Staphylothrombin, with varying binding affinity. Table 1 shows the various direct thrombin
inhibitors, with their molecular weight, structure, and binding affinities, as well as the active
organic groups that engaged in hydrogen bonding with Staphylothrombin.
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Figure 5: Identification of Potential Drugs Using Molecular Docking, Affinity, and
Laboratory Testing

Dabigatran and Argatroban were selected as the model ligand, because they have proven
clinical relevancy as previously noted. They also have widespread FDA approval for existent
thrombotic diseases, and they are easily obtained for research purposes. Several additional
derivatives of Dabigatran and Argatroban were tested, and a ligand that showed the greatest
promise was Ximelagatran, which is converted into the DTI melagatran in the presence of
physiological conditions. Ximelagatran was developed to specifically circumvent the detrimental
dietary and drug interactions that patients on warfarin (a rat poison) experienced (Thijssen,
1995). Warfarin is a long-term therapy in response to thrombosis, either from strokes, heart
attacks, or embolism. As a result, Ximelagatran was tested in long-term patients, and was
approved by the FDA for use in warfarin substitution therapy. However, after such long-term
use, Ximelagatran was pulled from marketing by the manufacturing company AstraZeneca due
to concerns over liver toxicity (Harenberg, 2009). In an acute setting, however, it would be
reasonable to administer Ximelagatran until a S. aureus infection is resolved. As shown on the
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table, it has a respectable binding affinity (8.1 kcal/mol), falling squarely between Dabigatran
(7.8) and Argatroban (8.4).
Finally, in addition to the three DTIs, a novel ligand was designed, and showed early
promise in the binding affinity, as well as the number of hydrogen bonds holding it in place. This
prototype molecule was preliminarily called Sulfamido, due to the inclusion of two sulfamide
active groups in its structure. Its structure can be found on the table. The most promising aspect
of this ligand is two-fold. First, it has a very high binding affinity to molecular weight ratio,
because of its very small profile. Second, it is largely constituted by amino acids, allowing for
readily available testing and further exploration.
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Table 1: Compounds and Their Binding Affinities
Compound
name

Molecular
Weight

Image

Binding Functional
Group

Number of
Hydrogen
Bonds

Binding
Affinity
(kcal/mol)

Argatroban

508.6 g/mol

Sulfonamide,
(sulfoxyl) Amino,
Acid.

6

-8.4

Dabigatran

626.3 g/mol

Acid, Amide
(carboxyl), Amide
(amino)

4

-7.8

Ximelagatran

473.6 g/mol

Amine, Ketone,
Aldehyde

3

-8.1

Sulfamido

363.4 g/mol

8

-8.3

Amine (Carbamine),
Ketone, sulfonyl,
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The molecular program PyMol was used to visualize the intricacies of the bound
molecules after the docking protocol was run. In addition, to obtain the binding groups and
number of hydrogen bonds connecting the ligand to the active site, a hydrogen bond search was
conducted using PyMol’s built in function. The result is these fantastic visualizations of bound
inhibitors in action. Shown in yellow, are the hydrogen bonds, going to acidic or basic residues
respectfully. While more hydrogen bonds tend to lend towards higher affinities, in the case of
Ximelagatran, there are only a few hydrogen bonds, but still a relatively stable binding affinity,
due to factors such as London Dispersion forces and overall fit of the enzyme.
Figure 6: Argatroban bound to the inhibitory pocket of Staphylothrombin
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Figure 7: Dabigatran bound to the inhibitory pocket of Staphylothrombin

Figure 8: Ximelagatran Bound to the inhibitory pocket of Staphylothrombin
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Figure 9: Sulfamido bound to the inhibitory pocket of Staphylothrombin

The binding energies and the overall fit of the enzyme will allow for an estimate of the
minimum inhibitory concentration required in the following section of the test. The general
prediction based off the binding affinities is that as the binding affinity to molecular weight ratio
increases, the lower the minimum inhibitory concentration required to prevent coagulation.
Therefore, this ligand, if synthesized, may have the lowest minimum inhibitory concentration of
all the drugs previously mentioned.
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2.2 Minimum Inhibitory Concentration
Much of this research revolves around the practical application of a commonly used
differential test known as the coagulase test (Siegrist, 2010). This test is used differentiate
Staphylococcus aureus from other, less pathogenic commensals in a clinical or diagnostic
setting. The coagulase test is made up of a few key ingredients. The first is lyophilized rabbit
plasma, which provides the prothrombin and fibrinogen necessary for coagulation. The second
major constituent is an EDTA solution. EDTA, or Ethylenediaminetetraacetic acid, is a
polyvalent chelating agent that sequesters calcium in the solution that would start an
inappropriate coagulation cascade. Coagulase, as previously noted, activates prothrombin (a
zymogen) and causes it to behave like the activated form, thrombin. Coagulase tests are usually
conducted with a positive and negative control, in this case a known quantity of S. aureus, a
known coagulase positive organism, and Staphylococcus saprophyticus, a known coagulase
negative organism.
Notably absent from this test was the ligand developed in the previous section. The
reason for this was an unfortunate time constraint, which meant the only ligands able to be tested
were those that were commercially available for purchase from Sigma-Aldrich. 5 mg of each
were purchased, excluding Dabigatran, where 10mg were purchased, in order to hone the
technique and protocol.
Before beginning the test, several determinations of the protocol were made
experimentally. First, it was experimentally tested if Dabigatran inhibited the growth or
metabolism of SA by adding 1 mL of a 1.8 mg/L solution to 1 mL of broth SA. This solution was
then plated and left overnight with a control containing just water and SA broth, and the next
morning the two produced an indistinguishable number of colonies. The same process was
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performed for DMSO, to ensure the minuscule volume of DMSO used to dissolve the drugs
would not confound the inhibition of the enzyme. After these preliminary tests were performed,
0.5 milliliters (mLs) of 85% rabbit plasma was used as the basis for the test. 0.1 mLs of a 0.5
McFarland Standard (McFarland, 1907), or approximately 1.5x10^8 S. aureus colonies, as this
was experimentally determined to be the least volume required for coagulation within a
reasonable time period. Aliquots of 3 different direct thrombin inhibitors were added, dissolved
in DMSO, with varying concentrations, to 30 tubes, 10 for each drug, with 1/5th dilutions
serially. A total of 0.4mL of the diluted ligand solution was added, bringing the whole solution in
the tube to 1mL. After 14 hours, in an incubator at 37 degrees Celsius, the results were collected.
“None” refers to no coagulation, VC stands for variable, or slight, coagulation, and C stands for
normal coagulation. Note the concentrations in Table 2 are in mg/ml for ease of calculations,
however in Table 3, they have been converted to Molarity.

Table 2: Concentration of ligands and inhibition of coagulation in mg/ml
Concentration

0.4

0.08

.016
3.2
.64
.128 25.6 5.12 1.024 .205
mg/ml
mg/ml mg/ml
μg/ml μg/ml μg/ml pg/ml pg/ml pg/ml pg/ml

Argatroban

None

None

None

None

None

None

VC

C

C

C

Dabigatran

None

None

None

None

None

VC

C

C

C

C

Ximelagatran

None

None

VC

VC

VC

C

C

C

C

C
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Table 3: Concentration of ligands and inhibition of coagulation in Molarity
Argatroban
Results:

None

Concentration
7.4E-4
in Moles/L
Dabigatran
Result:

None

Concentration
in Moles/L
6.4E-4
Ximelagatran
Results

None

Concentration
in Moles/L
8.4E-4

None

None

None

None

None

VC

C

C

C

1E-4

3E-05

6.1E-06

1.2E-06

2.43E-08

4.865E-11

9.7E-12

1.9E-12

3.91E-13

None

None

None

None

VC

C

C

C

C

1.3E-4

2.6E-5

5.1E-6

1.0E-6

2.04E-8

4.1E-11

8.2E-12

1.6E-12

3.3E-13

None

VC

VC

VC

C

C

C

C

C

1.7E-4

3.38E-05

6.8E-06

1.4E-06

2.7E-08

5.4E-11

1.1E-11

2.2E-12

4.4E-13

Dabigatran is shown in Table 4 to have about a 400x higher minimum inhibitory
concentration when compared to Argatroban, which is consistent with the binding affinity
theory, however on a much more significant scale. Ximelagatran in Table 5 has a much larger
minimum inhibitory concentration compared even to Dabigatran and would be at a concentration
impractical for clinical relevancy.
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Table 4: Minimum Inhibitory concentration for Dabigatran as Compared to Argatroban
0.0000012
0.000001
0.0000008
0.0000006
0.0000004
0.0000002
0
1
Dabigatran

Argatroban

Table 5: Minimum inhibitory Concentration for Ximelagatran as Compared to Argatroban
0.00018
0.00016
0.00014
0.00012
0.0001
0.00008
0.00006
0.00004
0.00002
0
1
Ximelagatran
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Dabigatran

CHAPTER 3: DISCUSSION AND CONCLUSION
3.1 Discussion
These results were largely within an expected range. Argatroban and Dabigatran behaved
within reason, with the reservation that minimum inhibitory concentration assays tend to be a
crude instrument for determining the relative effectiveness for an inhibitor. The major
disappointment was Ximelagatran, which showed promise in a molecular docking setting,
however in vitro demonstrated bizarre inhibition characteristics, even when standardized by
molarity in the solution. Despite the lack of resolution in this test, however, this can still hold
clinical relevance for one reason: Cost. Coagulase tests are regularly run in a hospital setting,
using patient plasma, and patient SA samples. The only additional variable is the addition of a
DTI solution, which is readily available in a hospital setting, and relatively available for a
laboratory. The benefit is that it adds in the ability to determine the ideal drug to use to best fit
the patient’s strain of SA. If the protocol was to be further standardized using a specific
concentration of thrombin, it could be used to track subtypes of MRSA or VRSA while also
providing a substantial chance of recovery for the patient.
Regarding the expected trend of binding affinity to molecular weight ratio being related
to requiring less of the drug to inhibit the coagulase enzyme, it seems to apply readily to
Dabigatran and Argatroban (Dabigatran has a lower affinity to molecular weight ratio than
Argatroban, therefore it requires more to cause inhibition) however, this did not apply to
Ximelagatran, which despite in a molecular docking program having a higher affinity to weight
ratio, as was seen previously required far more in order to obtain inhibition.
Some possible confounders are first that both Ximelagatran and Dabigatran have an
intermediary step in the body before being deposited into the bloodstream. For Ximelagatran it is
20

its conversion from Ximelagatran to a smaller molecule melagatran, and for Dabigatran, it is its
conversion from Dabigatran Etexilate, which is lipid soluble and readily digested and absorbed
into the intestines, to the much more water-soluble Dabigatran. While this may have played a
small role, it would have also played a role in the two molecule’s binding affinity, so the net
effect should be marginal.
An additional confounder for this protocol is the use of live S. Aureus species. SA is
known to produce several exoenzymes such as Staphylokinase, hemolysins, and leucocidins
(Tam, 2019). These all have the potential to play a possible role in partially deactivating or
rendering the drugs less effective in vitro. While this factor may seem to render this test useless
due to its unreliability, this is part of the goal of this test: to test drugs that work on live SA
virulence factors, not just the enzyme held in isolation. If a certain drug is enzymatically broken
down in the presence of SA species, this would be key information to know before it is given to a
patient in a clinical setting.
Finally, due to the time constraints the experiment had to exclude the ligand outlined in
section 2.1. This ligand showed promise in the molecular docking tests, and it would have been
ideal to have tested it using the methods outlined in the minimum inhibitory concentration
section. While unsuccessful, this screening strategy could theoretically be used to test a larger
quantity of ligands.
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3.2 Conclusion
The intent of this research was to provide an overview of the existing literature on testing
DTIs on Staphylococcus Aureus infections, as well as provide a background and context for the
mechanism of both Staphylothrombin activation and inhibition. While there are several cases in
the literature where DTIs were tested in a clinical setting, the final intent of this thesis was to
examine the possibility of using an existent test in order to titrate a dose and type of DTI to use
on certain subtypes of SA. Using a molecular screening process against a ligand library, several
potential drugs were identified based on their relative affinity. Finally, they were tested in a
laboratory setting, to mixed results.
This paper has contributed to the literature by proposing a new protocol for use of the
coagulase test in the context of a clinical setting and provided a useful set of chemical guideline
and potential pitfalls to avoid. Future work should involve refining the process to eliminate any
potential confounding factors, as well as add additional layers of quantification, such as time,
refractive index, or absorption in order to increase resolution of this test. Future work should also
include a preliminary ligand like the one outlined in the paper, in order to test the efficacy of this
protocol in a laboratory setting. Finally, it would be ideal after obtaining a promising MIC to use
X-ray crystallography to see the exact binding of DTIs to Staphylothrombin.
Staphylococcus aureus is a dangerous and robust infectious microorganism, and
alternative treatments to traditional antibiotics must be considered in order to treat and cull its
spread in hospitals and the population at large. MRSA and VRSA are a ubiquitous threat in a
nosocomial setting, and this paper has hopefully contributed to the body of data that can be
called upon for further study.
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